法尼醇X受体及其激动剂与肝脏疾病

肝脏 ›› 2021, Vol. 26 ›› Issue (11): 1293-1297.

法尼醇X受体及其激动剂与肝脏疾病

贾锶琦, 窦晓光

110022 沈阳中国医科大学附属盛京医院感染科

收稿日期:2021-03-30 出版日期:2021-11-30 发布日期:2021-12-24
通讯作者: 窦晓光,Email:guang40@163.com

Received:2021-03-30 Online:2021-11-30 Published:2021-12-24

摘要/Abstract

摘要： 法尼醇X受体( farnesoid X receptor,FXR)又名胆汁酸受体,是一种配体激活转录因子。FXR激动剂作用于FXR后,激活一系列复杂的下游通路,其代谢产物参与调节胆汁酸、糖类、脂质的稳态,进而在肝脏组织炎症、纤维化、再生及癌变过程中起到重要的调节作用,影响肝脏代谢性疾病的发生发展。寻找治疗靶点更精确且高效低毒的FXR激动剂,治疗肝脏代谢性疾病是当前的研究热点。本文将主要围绕FXR对代谢的调节及其与肝脏疾病的关系及其激动剂的研究进展进行讨论。

贾锶琦, 窦晓光. 法尼醇X受体及其激动剂与肝脏疾病[J]. 肝脏, 2021, 26(11): 1293-1297.

参考文献

[1] Ding L, Yang L, Wang Z, Huang W, et al. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B, 2015,5(2): 135-144.
[2] Gabler M, Kramer J, Schmidt J,et al.Allosteric modulation of the farnesoid X receptor by a small molecule. Sci Rep, 2018,8(1):6846.
[3] Wong VW.Current prevention and treatment options for NAFLD. Adv Exp Med Biol, 2018,1061:149-157.
[4] Shin DJ, Wang L. Bile acid-activated receptors: a review on FXR and other nuclear receptors.Handb Exp Pharmacol,2019,256:51-72.
[5] Sagar NM, McFarlane M, Nwokolo C, et al.Mechanisms of triglyceride metabolism in patients with bile acid diarrhea. World J Gastroenterol, 2016,22(30):6757-6763.
[6] Kim T, Nason S, Holleman C, et al. Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21.Diabetes,2018,67(9):1773-1782.
[7] Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial. Lancet,2018,391(10126):1174-1185.
[8] Brunt EM, Kleiner DE, Wilson LA, et al. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis research network treatment trials. Hepatology,2019,70(2):522-531.
[9] Fiorucci S, Biagioli M, Zampella A, et al.Bile acids activated receptors regulate innate immunity. Front Immunol, 2018,9:1853.
[10] Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology, 2015,148(4):751-761.e8.
[11] 陈科全, 周碧瑶,陈雅莹,等.法尼酯衍生物X受体活化对肝星状细胞TIMP-1、TIMP-2及MMP-2表达的调节作用. 临床肝胆病杂志, 2013,29(04): 290-293.
[12] Roth JD, Feigh M, Veidal SS, et al. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol,2018,24(2):195-210.
[13] Hodge RJ, Nunez DJ. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype? Diabetes Obes Metab, 2016,18(5):439-443.
[14] Xin XM, Zhong MX, Yang GL, et al. GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells. World J Gastroenterol, 2014,20(42):15727-15735.
[15] Eaton JE, Vuppalanchi R, Reddy R, et al. Liver injury in patients with cholestatic liver disease treated with obeticholic acid. Hepatology,2020,71(4):1511-1514.
[16] Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in non-cirrhotic patients with NASH: a phase 2 randomized controlled trial. Hepatology,2020,72(1):58-71.
[17] Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicenter, randomized, placebo-controlled phase 3 trial. Lancet,2019,394(10215):2184-2196.
[18] Tully DC, Rucker PV, Chianelli D, et al. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J Med Chem,2017,60(24):9960-9973.
[19] Badman MK, Chen J, Desai S, et al.Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers. Clin Pharmacol Drug Dev, 2020,9(3):395-410.
[20] Carino A, Biagioli M, Marchianò S,et al.Disruption of TFGbeta-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand. Pharmacol Res, 2018,131:17-31.